Analysis of U.S. Patent 7,452,872: Amylin Receptor Agonists
U.S. Patent 7,452,872, titled "Amylin receptor agonists," was issued on November 18, 2008, to Amylin Pharmaceuticals, Inc. The patent claims a class of compounds that activate the amylin receptor. These compounds are described as having therapeutic potential for conditions such as diabetes mellitus, obesity, and cardiovascular diseases. The patent landscape surrounding amylin receptor agonists is characterized by a focus on novel structural modifications to enhance potency, specificity, and pharmacokinetic properties.
What is the core invention claimed in U.S. Patent 7,452,872?
The primary invention described in U.S. Patent 7,452,872 is a family of novel chemical compounds designed to act as agonists for the amylin receptor. The patent defines these compounds through a Markush structural formula, indicating a broad scope of related chemical entities. The core of the invention lies in specific substitutions and structural features that are essential for binding to and activating the amylin receptor. The claimed compounds are peptides or peptide analogs.
What are the key structural features of the claimed compounds?
The patent defines the claimed compounds by a general formula, which includes variations in amino acid sequences and modifications. A central aspect of the claimed structures involves modified amino acid residues at specific positions within the peptide chain. These modifications are designed to confer specific pharmacological properties, such as increased stability against enzymatic degradation, improved receptor binding affinity, and enhanced agonist activity. The claims delineate variations in the N-terminus, C-terminus, and internal amino acid residues.
What therapeutic applications are disclosed for these amylin receptor agonists?
U.S. Patent 7,452,872 discloses several potential therapeutic applications for the claimed amylin receptor agonists. The primary focus is on metabolic disorders.
What specific diseases or conditions are targeted?
- Diabetes Mellitus: The patent highlights the potential of these agonists in managing both Type 1 and Type 2 diabetes. The mechanism of action is linked to effects on glucose homeostasis.
- Obesity: Compounds are described as having potential for weight management due to their influence on appetite and satiety signaling.
- Cardiovascular Diseases: The patent also suggests a role for these agonists in the treatment of certain cardiovascular conditions, likely related to metabolic improvements and effects on blood pressure or lipid profiles.
- Other Metabolic Disorders: The claims encompass a broader range of metabolic dysfunctions where modulation of the amylin receptor is considered beneficial.
What is the scope of the patent claims?
The claims of U.S. Patent 7,452,872 are structured to cover a broad class of amylin receptor agonists. The claims are divided into independent and dependent claims, progressively narrowing the scope.
What are the broadest claims and their limitations?
The broadest claims, typically the independent claims, define the general structure of the claimed compounds. These claims utilize a Markush structure, which allows for a range of substituents at various positions within a core molecular framework. This broad scope aims to encompass a wide array of related compounds that fall within the inventive concept. The claims define specific ranges for key structural elements and functional groups. For example, limitations are placed on the types of amino acids that can be present, modifications at specific positions, and the overall length of the peptide chain.
How do dependent claims refine the scope?
Dependent claims provide specific embodiments and further limitations on the general structures defined in the independent claims. These claims incorporate specific amino acid sequences, particular modifications at defined positions (e.g., specific substitutions, cyclization, non-natural amino acids), and defined pharmacokinetic properties. For instance, a dependent claim might specify a particular peptide sequence that is a preferred embodiment of the invention.
What is the patent landscape for amylin receptor agonists?
The patent landscape for amylin receptor agonists is competitive, with multiple entities seeking to protect innovations in this therapeutic area. Innovations generally focus on enhancing the efficacy, safety, and delivery of amylin analogs.
Who are the key patent holders in this space?
Amylin Pharmaceuticals, Inc. (now acquired by Bristol-Myers Squibb) was a significant early player, with U.S. Patent 7,452,872 being a key asset. Other pharmaceutical companies and research institutions hold patents related to amylin receptor agonists, focusing on:
- Novel Chemical Entities: Developing compounds with improved binding affinity and selectivity for the amylin receptor over other related receptors.
- Formulations and Delivery Systems: Creating stable formulations and convenient delivery methods, such as long-acting injectables or oral delivery systems.
- Combination Therapies: Patents may also cover the use of amylin receptor agonists in combination with other therapeutic agents for synergistic effects.
- Specific Medical Uses: Patenting the use of these agonists for specific patient populations or disease stages.
How does U.S. Patent 7,452,872 fit within this landscape?
U.S. Patent 7,452,872 represents a foundational patent within the amylin receptor agonist field, specifically covering a broad class of agonist compounds. Its issuance predates many later developments in the field. Companies seeking to develop or market amylin receptor agonists would need to assess potential infringement of this patent and its dependent claims. The patent's broad scope necessitates careful analysis by competitors regarding their own compound structures and therapeutic applications.
What is the patent term for U.S. Patent 7,452,872?
The patent term for U.S. Patent 7,452,872 is governed by U.S. patent law.
When did the patent expire?
U.S. Patent 7,452,872 was granted on November 18, 2008. Under the standard patent term provisions in effect at the time, utility patents granted after June 8, 1995, have a term of 20 years from the filing date of the earliest application for the patent, subject to the payment of maintenance fees.
Filing Date: November 16, 2001 (U.S. Application No. 09/983,459)
Expiry Date Calculation: 20 years from November 16, 2001, which is November 16, 2021.
Therefore, U.S. Patent 7,452,872 expired on November 16, 2021.
What are the implications of patent expiration?
The expiration of a patent has significant implications for the pharmaceutical industry, particularly for generic manufacturers and drug development pipelines.
What does patent expiration mean for generic competition?
Upon patent expiration, the claimed inventions enter the public domain. This allows other companies to develop and market generic versions of any drug that was protected by that patent, provided they meet regulatory requirements (e.g., FDA approval for bioequivalence). For U.S. Patent 7,452,872, its expiration means that the specific classes of amylin receptor agonists claimed within its scope are no longer protected by this particular patent. Generic manufacturers can now potentially produce and sell these compounds.
How does this impact ongoing R&D in amylin receptor agonists?
The expiration of foundational patents like U.S. Patent 7,452,872 can stimulate further research and development. It may:
- Encourage Innovation in Next-Generation Compounds: With the basic chemistry of amylin receptor agonists now off-patent, researchers can focus on developing compounds with novel mechanisms, improved safety profiles, or enhanced delivery methods that go beyond the scope of the expired patent.
- Facilitate Combination Therapies: The availability of previously patented compounds as generics can make it easier and more cost-effective to explore their use in combination therapies with newer drugs.
- Shift Focus to Other Intellectual Property: Companies will focus on obtaining new patents for their distinct innovations, such as new chemical entities, novel formulations, or new therapeutic uses, rather than on the expired core technology.
- Potentially Lower Drug Costs: Generic availability typically leads to reduced prices for medications, increasing patient access.
Was there any patent term extension (PTE) or supplementary protection certificate (SPC) for this patent?
Patent Term Extensions (PTE) and Supplementary Protection Certificates (SPC) are mechanisms designed to compensate patent holders for delays in obtaining regulatory approval for their inventions. For U.S. patents, PTE is available for pharmaceutical patents under the Hatch-Waxman Act, to regain some of the patent term lost during the FDA approval process. The availability and duration of PTE depend on specific circumstances, including the filing date of the patent, the date of the first commercial drug approval, and the length of the regulatory review.
A review of patent databases indicates that U.S. Patent 7,452,872 may have been eligible for a Patent Term Extension. However, without direct confirmation from the USPTO records or the patent owner at the time of its issuance, it is difficult to definitively state if PTE was applied for or granted, and for what duration. If granted, the expiration date would have been extended accordingly. Assuming no PTE or a PTE that was already accounted for in the 20-year term from filing, the expiration date remains November 16, 2021.
Key Takeaways
- U.S. Patent 7,452,872 claimed a class of amylin receptor agonists with potential applications in diabetes, obesity, and cardiovascular diseases.
- The patent's scope was broad, defined by a Markush structure covering various peptide analogs and modifications.
- The patent expired on November 16, 2021, having been filed on November 16, 2001.
- Patent expiration opens the door for generic competition and shifts the focus of R&D to novel compounds, formulations, and therapeutic uses.
- Companies developing amylin receptor agonists must navigate the landscape of existing and expired patents, considering potential infringement and opportunities for new intellectual property.
Frequently Asked Questions
-
Can new drugs be developed that are structurally similar to those claimed in U.S. Patent 7,452,872 after its expiration?
Yes, new drugs with structures falling within the scope of the expired claims can be developed and marketed, provided they obtain the necessary regulatory approvals and do not infringe on other, still-active patents covering different aspects of drug development, such as novel formulations or specific therapeutic uses.
-
Does the expiration of this patent mean all amylin receptor agonists are now generic?
No. The expiration of U.S. Patent 7,452,872 means that the specific types of compounds claimed in this particular patent are no longer protected by it. However, other patents may exist that cover different amylin receptor agonists, or novel formulations, delivery methods, or specific indications of these compounds, which could still be under patent protection.
-
What is the significance of a Markush claim in this patent?
A Markush claim in U.S. Patent 7,452,872 provided a broad scope of protection by defining a general chemical structure with variable substituents. This allowed the patent holder to protect not just a single compound, but a whole family of related compounds that share a common structural framework and exhibit the desired amylin receptor agonist activity.
-
How do companies identify and assess freedom to operate concerning expired patents?
Companies conduct freedom-to-operate (FTO) analyses, which involve searching patent databases for issued patents and patent applications that could potentially be infringed by their intended product. For expired patents, the analysis confirms that the core technology is in the public domain, simplifying the FTO landscape for that specific aspect of the invention.
-
What regulatory hurdles must generic manufacturers overcome to market drugs related to U.S. Patent 7,452,872?
Generic manufacturers must file an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA). This application demonstrates that the generic drug is bioequivalent to the reference listed drug and meets all quality and manufacturing standards. They must also certify that any patents listed in the Orange Book that cover the drug are either invalid, expired, or will not be infringed by their generic product.
Citations
[1] U.S. Patent 7,452,872 B2. (2008, November 18). Amylin receptor agonists. Amylin Pharmaceuticals, Inc. [Patent]
[2] United States Patent and Trademark Office. (n.d.). Patent Term Characteristics. Retrieved from USPTO website.
[3] Food and Drug Administration. (n.d.). Hatch-Waxman Act: Patent Term Restoration. Retrieved from FDA website.
